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ABSTRACT
Background. Hypertension is a major risk 
for the development and progressivity complication 
of macro and microvascular of diabetes mellitus. 
Renin-angiotensin-aldosteron system (RAAS), 
insulin resistance, endothelial dysfunction and 
autonomic nervous dysfunction play an important 
part in the pathogenesis of hypertension and type 2 
diabetes mellitus. In RAAS, increased angiotensin II 
constricts arterioles, raises total peripheral 
resistance and blood volume. The rise in 
intravascular volume increases risk of hypertension. 
Glucotoxicity or hyperglycemia in type 2 diabetes 
mellitus can increases angiotensin II levels.
Aim. To evaluate plasma angiotensin II 
levels in type 2 diabetes mellitus women with or 
without hypertension.
Methods. Cross sectional design was 
conducted on subjects from outpatients' women with 
type 2 diabetes mellitus at endocrinology clinic, Dr. 
Sardj i to  General  Hospital ,  Yogyakarta.  
Hypertension was assessed using criteria from 
Seventh Joint National Committee (2003). ELISA 
sandwich method was used to measure plasma 
angiotensin II levels from blood vein. Differences 
between groups were compared by student's 
unpaired t-test and Mann-Whitney test.
Results. Among 60 subjects, there are 30 
with hypertension (50%) and 30 without 
hypertension (50%). Mean age were 54.11 ± 3.36 
years old. Plasma angiotensin II levels was higher in 
women with type 2 diabetes mellitus with 
hypertension than without hypertension although 
significance was not reached (0.30 ± 0.15 ng/mL vs. 
0.28 ± 0.18 ng/mL, p= 0.93).
Conclusion. The plasma angiotensin II 
levels are not significantly different between type 2 
diabetes mellitus women with or without 
hypertension.
Key words: hypertension, plasma angiotensin II, 
type 2 diabetes mellitus, women
INTRODUCTION
High prevalence of diabetes was a serious 
problem in the world since twenty years ago. Type 2 
diabetes or non-insulin dependent of diabetes 
mellitus (NIDDM) is the most common type of 
diabetes (85-90%). In 2003, the world health 
organization (WHO) predicted that in Indonesia 
there were 5.1% or equals to 194 million people of 
20-79 years old suffering from diabetes and this 
tends to increase in the year 2025 (almost 333 
million people). Diabetes mellitus and hypertension 
were risk factors for morbidity and mortality from 
complication of cardiovascular disease,  
cerebrovascular disease and chronic kidney disease. 
Increasing normal systolic blood pressure of about 
20 mmHg or diastolic pressure of about 10 mmHg in 
12 years had correlation with high risk mortality due 
to coronary heart disease and stroke³. Many factors 
may influence blood pressure. Renin-angiotensin-
aldosteron system (RAAS) is one of the factors that 
have an important role in controlling blood pressure 
4and sodium homeostasis .
Prevalence of hypertension in population 
with diabetes is greater than without diabetes. 
Hypertension is the most important factor in 
progressivity of chronic complications of diabetes, 
e i ther  macrovascular  or  microvascular  
4complications . The prevalence of diabetes mellitus 
increases in women because high prevalence of 
obesity in women, polycystic ovarii syndrome, 
gestational diabetes or premenopausal (due to the 
5effect of low estrogen) . 
The decreasing of estrogen in women 
influence high activity RAAS and then increasing 
angiotensin II constricts arterioles, raises total 
peripheral resistance and blood volume. The rise in 
intravascular volume increases risk of hypertension. 
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Table 1. Characteristic of Study Subjects
Variables  Mean  ± SD  
Median (min-max)  
Frequency
n (%)
Status of Hypertension  
? With hypertension  
? Without hypertension  
   
30 (50)
30 (50)
Status of type 2 diabetes:  <5 years  years
 With oral antidiabetic (OAD) drugs
 With insulin
 With OAD + insulin
 
  26 (43)
34 (57)
18 (30)
20 (34)
22 (36)
Age (years)
 
54.11 ± 3.36
  Height (cm)
 Weight (kg)
 BMI (kg/m²)
 
155 (144-167)
 57 (40-83)
 24.25 ± 3.05
 
 
Systolic Blood Pressure (mmHg)
 
133.24 ± 11.36
  Diastolic Blood Pressure (mmHg)
 
79.19 ± 8.07
  Fasting Blood Sugar (mg/dL)
 
108.00 (78.00-292.00) 
  2 Hour Post
 
Prandial Blood Sugar (mg/dL)
 
140.50 (69.00-362.00) 
  Plasma Angiotensin II (ng/mL)
 
0.30 ± 0.19
  Total Cholesterol (mg/dL)
 
182.14 ± 36.28
  LDL
 
Cholesterol (mg/dL)
 
118.09 ± 19.24
  HDL Cholesterol (mg/dL) 60.08 ± 26.09Triglycerida (mg/dL) 139.00 (75-267)
>5 
SD= standard deviation, BMI= body mass index, LDL= low density lipoprotein, 
HDL= highDensity Lipoprotein.
Glucotoxicity or hyperglycemia in NIDDM can 
5increases angiotensin II levels .
The aim of the study was to evaluate plasma 
angiotensin II levels in type 2 diabetes mellitus 
women with or without hypertension.
RESEARCH METHODS
The study was performed as a cross-
sectional study. The sample was selected 
consecutively from outpatients' women with the age 
22-60 years in endocrinology clinic at DR Sardjito 
General Hospital – Yogyakarta using the ADA 2010 
criteria of diabetes mellitus and JNC-7 2003 criteria 
of hypertension. The data was obtained from June to 
December 2010 after subjects sign the informed 
consent.
The protocol of the study had been approved 
by the human research ethics committee of the 
Faculty of Medicine Gadjah Mada University – Dr. 
Sardjito General Hospital. Excluded from the study 
were women who had congestive heart failure, 
chronic kidney disease, malignancy, liver cirrhosis, 
sepsis, taking hormone drugs or contraceptions, 
pregancy and lactating women.
STATISTICAL  ANALYSIS
The mean difference of plasma angiotensin 
II levels between type 2 diabetes mellitus women 
with hypertension and without hypertension were 
analyzed by independent t-test on data with normal 
distribution or by Mann- Whitney U test on data with 
abnormal distribution. Kolmogorov Smirnov's test 
was perfomed to assess data distribution. All 
statistical analyses were performed with SPSS 13.0 
for Windows (SPSS, Chicago, IL) and P values of 
6<0.05 were considered significant .
RESULTS
A total of 60 individuals with mean age of 
54.11 ± 3.36 years were studied; from among them 
30 (50%) were type 2 diabetes mellitus women with 
hypertension. The characteristic of the study 
subjects can be seen in the Table 1.
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Table 2. Data of Study Subjects with Type 2 Diabetes Mellitus with or without
Hypertension
Variables  Type 2 diabetes 
mellitus with 
hypertension 
(n=30) 
Type 2 diabetes 
mellitus without 
hypertension 
(n=30) 
P CI 95% 
Age (years) 53.45 ± 3.17 54.88 ± 3.45 0.067 ** -1.43 sd 0.11 
Height (cm) 
Weight (kg) 
BMI (kg/m²) 
155.97 ± 5.05 
61.41 ± 8.99 
25.14 ± 2.76 
155.97 ± 5.05 
41.41 ± 8.99 
18.04 ± 2.76 
0.289* 
0.017 * 
0.019 ** 
 
 
-3.03 sd -0.28 
Systolic BP (mmHg) 144.25 ± 5.49 113.82 ± 6.04 0.00 ** -22.2 sd -16.9 
Diastolic BP (mmHg) 93.25 ± 4.74 76.18 ± 4.93 0.00 ** -15.1 sd -10.6 
Fasting BS (mg/dL)  157.88 ± 49.34  101.88 ± 27.43 0.00 *  
2HPP BS (mg/dL) 235.92 ± 83.97 124.81± 51.43 0.00 *  
Angiotensin II (ng/mL) 0.30 ± 0.15   0.28 ± 0.18 0.93 ** -0.94 sd 0.08 
Total Cholesterol 
(mg/dL) 
183.32 ± 33.81 180.74 ± 39.45 0.765 ** -14.6 sd 19.8 
LDL Cholesterol(mg/dL) 115.88 ± 18.24 120.71 ± 20.32 0.285 ** -13.7 sd 4.11 
HDL 
Cholesterol(mg/dL) 
67.62 ± 26.79 51.20 ± 22.51 0.006 ** 4.83 sd 28.01 
Triglycerida(mg/dL) 128.08 ± 35.35 115.88 ± 18.24 0.007 *  
 BMI= body mass index, BP= blood pressure, BS= blood sugar, 2HPP= 2 hour post prandial,
LDL= low density lipoprotein, HDL= high density lipoprotein, *= Mann-Whitney U test, **=
Independent t-test, CI= confidence interval
Table 2 showed that plasma angiotensin II levels 
were higher in type 2 diabetes mellitus women with 
hypertension than without hypertension although 
without significance (0.30 ± 0.15 ng/mL vs. 0.28 ± 
0.18 ng/mL. p=0.93).
DISCUSSION
Premenopausal women with low estrogen 
can increase activity of RAAS. That condition 
causes the losing a cardio-protective effect, endotel 
function, and a low response of coronary 
5vasodilation . Pathophysiology of hypertension 
from RAAS activity is one of the factors that have 
important role in insulin resistance or metabolic 
syndrome as a part form type 2 diabetes mellitus. 
Glucotoxicity or hypergycemia in type 2 diabetes 
mellitus can increase RAAS activity and plasma 
7angiotensin II .
The prevalence rate of plasma angiotensin 
II levels was higher in type 2 diabetes mellitus with 
hypertension (0.30 ± 0.15 ng/mL) than without 
hypertension (0.28 ± 0.18 ng/mL) although it did not 
show no significant statistically (p=0.93). These 
prevalence rates were similar to the ones observed 
8by Bluher et al  (0.32 ± 0.21 ng/mL vs. 0.31 ± 0.14 
ng/mL. p>0.05). 
The cross-sectional nature of the present 
study has precluded the causal inferences regarding 
the determination of the prevalence rate of high 
plasma angiotensin II in type 2 diabetes mellitus 
with hypertension in a group of individuals' 
representativeness of the national population. 
Participant selection, on the other hand, has reduced 
the generalizability of the findings. Large 
prospective studies in various districs are needed to 
better evaluate the prevalence increasing plasma 
angiotensin II in type 2 diabetes mellitus with 
hypertension. The second limitation of this study is 
the potential bias due to missing values in some 
variables. The large number of participants, 
however, may have compensated for these potential 
biases to some extent.
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CONCLUSION
There was no significant differences of 
plasma angiotensin II levels in women  with type 2 
diabetes mellitus women who also have 
hypertension when compared to the ones without 
hypertension. However the findings of the present 
study provide alarming evidences for health 
professionals and policy makers about the high 
prevalence of high plasma angiotensin II in type 2 
diabetes mellitus in our population. Preventive and 
treatment strategies, notably in women, are urgently 
needed to prevent and promote healthy lifestyle 
habits.
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ABSTRACT
Background. Tumor Necrosis Factor-α 
(TNF-α), a pro-inflammatory cytokine produced by 
monocyte is increased in osteoarthritis synovial 
fluid. Curcuminoid from Curcuma domestica Val. 
suppresses the secretion of TNF-α. 
Objective. The purpose of this study was to 
investigate the suppression effect of curcuminoid 
from Curcuma domestica Val on synovial fluid 
monocyte's TNF-α secretion compared to diclofenac 
sodium in knee osteoarthritis 
Methods. A prospective randomized open 
end blinded evaluation (PROBE) method was 
applied. Subjects were patients with knee 
osteoarthritis visiting Rheumatology Clinic Dr. 
Sardjito Hospital and Wirosaban Hospital 
Yogyakarta. Curcuminoid 30 mg three times daily or 
diclofenac sodium 25 mg three times daily were 
administered for 4 weeks. The level of TNF-α 
secreted by synovial fluid's monocytes were 
measured by ELISA before and after treatment. 
Results. A total of 80 subjects were enrolled, 
39 subjects on curcuminoid treatment groups and 41 
subjects on diclofenac sodium group. Seven subjects 
were dropped out, 5 from the curcuminoid group and 
2 from the diclofenac sodium group. There was a 
significant decrement of TNF-α level during 4 weeks 
treatment in both groups (p< 0.001 respectively). 
There was no significant difference on TNF-α levels 
between groups (p= 0,237), neither in 50% 
decrement of TNF-α levels (p= 518).
Conclusion. The effect of curcuminoid in 
decreasing TNF- α level on patients with 
osteoarthritis is similar with sodium diclofenac.
Keywords: osteoarthritis-monocyte-TNF-α-
curcuminoid-diclofenac sodium
INTRODUCTION 
Osteoarthritis (OA) is a degenerative joint 
disease that has been related to damage of the joint's 
cartilage. The manifestations of osteoarthritis such 
as changes in morphology, biochemistry, molecular 
and biomedical aspects of cells and matrixes result 
in fibrillation, ulceration, thinning of joint's 
cartilage, sclerosis and formation of osteophyte and 
1  bone cyst .
The prevalence of knee osteoarthritis from 
radiologic examination in Indonesia is high, 
approximately 15.5% in man and 12.7% in woman. 
Due to the high level of prevalence and its chronic 
progressive characteristic, osteoarthritis has been 
contributing a big impact, socially and 
economically, in developed countries as well as in 
developing countries. In Indonesia, the estimated 
numbers of elderly who suffers from disability due 
2to OA, is around 1 until 2 million people . 
The role of cytokines in OA contributes 
major effects to the incident and disease 
progressiveness. Tumor necrosis factor-α (TNF-α) 
and interleukin-1 (IL-1) has been suspected to have 
responsible as mediators for chondrocyte response 
3in this joint disease . In osteoarthritis, IL-1 and TNF-
α activate the degradating enzymes such as 
metalloproteinase, collagenase, gelatinase and 
aggrecanase that can generate the inflammatory 
4responses in the joint . Both cytokines, IL-1β and 
TNF-α, has been shown to play roles in cartilage 
destruction and inflammatory process'. An 
